Myoki

Myoki

Evidence & Status

  • Moderate Evidence
  • Moderate

At a Glance

A synthetic peptide with preclinical muscle-atrophy research and a small, short randomized human study; its proposed human mechanism remains unestablished.

Plain English

Myoki was studied in adults with muscle atrophy, not as an established bodybuilding or older-adult sarcopenia treatment. The trial reported a lean-mass difference, but functional findings need caution and long-term safety is unknown. The authors were employed by Caregen.

Overview

Myoki is a synthetic seven-residue peptide, EAEYEHL, studied in muscle-atrophy research. A peer-reviewed publication reports C2C12 cell experiments, a SAMP8 mouse study and a randomized human trial. Laboratory myostatin binding is a working hypothesis, not an established causal mechanism for the human findings. All five listed authors disclosed employment by Caregen.

Research Summary

The 12-week double-blind, placebo-controlled trial randomized 80 adults; 75 entered per-protocol efficacy analyses. Both groups received arginine and maltodextrin, with Myoki additionally present in the experimental formulation. Outcomes included DEXA lean mass, six-metre walking performance, handgrip strength and serum biomarkers. The reported adjusted between-group lean-mass difference was 705.8 g in favour of Myoki. Walking and handgrip confidence intervals reached or crossed zero despite reported significant p-values, so these do not establish unequivocal functional benefit. The relatively young cohort limits extrapolation to sarcopenia in older adults. Treatment-emergent adverse events occurred in 10/40 experimental versus 7/40 control participants; all were reported as mild and resolved, with no serious or study-product-related events reported. This short trial does not establish long-term safety. Cell findings and mouse histology/marker findings are preclinical; the publication did not establish that myostatin binding caused the human outcomes. All five authors disclosed Caregen employment.

Research Areas

  • Muscle atrophy
  • Lean-mass research
  • Preclinical muscle biology

Safety & Risks

Reported Side Effects

  • Mild treatment-emergent adverse events were reported in both trial groups; none were assessed as study-product-related
United States
Research evidence does not establish an approved clinical use in this record.
United Kingdom
Current authorization status not established in this record.
Australia
Current authorization status not established in this record.
Canada
Current authorization status not established in this record.

Citations & Sources